The estimated Net Worth of Stuart Naylor is at least $6.14 Milione dollars as of 14 January 2024. Stuart Naylor owns over 23,750 units of MeiraGTx plc stock worth over $2,394,047 and over the last 6 years he sold MGTX stock worth over $1,504,886. In addition, he makes $2,245,570 as Chief Development Officer at MeiraGTx plc.
Stuart has made over 18 trades of the MeiraGTx plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 23,750 units of MGTX stock worth $98,800 on 14 January 2024.
The largest trade he's ever made was exercising 115,000 units of MeiraGTx plc stock on 7 January 2024 worth over $478,400. On average, Stuart trades about 18,234 units every 65 days since 2018. As of 14 January 2024 he still owns at least 575,492 units of MeiraGTx plc stock.
You can see the complete history of Stuart Naylor stock trades at the bottom of the page.
Dr. Stuart Naylor Ph.D. serves as Chief Development Officer of the Company. From April 2015 to April 2016, Dr. Naylor was Chief Executive Officer of Athena Vision Limited, a biotechnology company. From June 2013 to April 2015, Dr. Naylor served as managing director of Coltivare Ltd., a healthcare consulting company. From 2008 to 2013, Dr. Naylor was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, a gene therapy company. Prior to joining Oxford BioMedica plc, Dr. Naylor focused on translational cancer research at the Institute of Cancer Research in London. Dr. Naylor has a B.S.C. in microbiology and virology from the University of Warwick, an M.S. in Immunology from Kings College London, and a Ph.D. from the Imperial Cancer Research Fund laboratory studying ovarian cancer and cytokine biology.
As the Chief Development Officer of MeiraGTx plc, the total compensation of Stuart Naylor at MeiraGTx plc is $2,245,570. There are 5 executives at MeiraGTx plc getting paid more, with Alexandria Forbes having the highest compensation of $8,480,260.
Stuart Naylor is 57, he's been the Chief Development Officer of MeiraGTx plc since 2019. There are 10 older and 7 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
Stuart's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus e Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
MeiraGTx plc executives and other stock owners filed with the SEC include: